H
Hope Medicine
Science-driven clinical stage biopharmaceutical company
About Hope Medicine
Hope Medicine Inc. (HopeMed) is a clinical-stage biotechnology company focused on developing innovative therapies targeting the prolactin receptor. Based in major innovation hubs in China, the company leverages a deep understanding of disease biology and translational medicine, stemming from decades of scientific research led by Professor Rui Ping Xiao at Peking University. HopeMed's core product, HMI 115, is a potential first-in-class human antibody aimed at treating endometriosis, androgenic alopecia, and other diseases associated with dysregulated prolactin signaling. The company operates in the biopharmaceutical sector, serving patients with unmet medical needs. Its business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through licensing agreements, such as the exclusive worldwide license with Bayer AG, and future sales of approved treatments.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2024 | $28M | $280M | Chuangxin Gongchang · Ennovation Ventures · VMS Group · Trustbridge Partners | ↗ |
| SERIES BOther financing | Nov 2023 | $0 | — | Qiming Venture Partners | — |
Growth signals
Latest recorded traffic for Hope Medicine is 530 monthly website visits, down 75.9% over the last three months. Hope Medicine's team grew 11.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hope Medicine in the Pudong ecosystem
The Hope Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Trustbridge Partners
Qiming Venture Partners
Grand Flight Investment
Sinovation Ventures
Highlight Capital
Chuangxin Gongchang- EVEnnovation Ventures
VMS Group
Beijing Zhongyin Technology
Wuxi Innovation Investment Group- HCHuairou Science City
Other known investors1 additional known investor
Peking University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hope Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hope Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








